A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment.

Trial Profile

A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms MARIGOLD
  • Sponsors Roche
  • Most Recent Events

    • 15 Jun 2016 Results published in the JAMA Psychiatry
    • 21 Oct 2014 Primary endpoint (Change in Montgomery Asberg Depression Rating Scale (MADRS)) has been met according to results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top